Scott Pain

896 total citations · 1 hit paper
18 papers, 461 citations indexed

About

Scott Pain is a scholar working on Cognitive Neuroscience, Experimental and Cognitive Psychology and Molecular Biology. According to data from OpenAlex, Scott Pain has authored 18 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cognitive Neuroscience, 9 papers in Experimental and Cognitive Psychology and 3 papers in Molecular Biology. Recurrent topics in Scott Pain's work include Sleep and Wakefulness Research (11 papers), Sleep and related disorders (9 papers) and Circadian rhythm and melatonin (3 papers). Scott Pain is often cited by papers focused on Sleep and Wakefulness Research (11 papers), Sleep and related disorders (9 papers) and Circadian rhythm and melatonin (3 papers). Scott Pain collaborates with scholars based in Switzerland, United States and France. Scott Pain's co-authors include Gary Zammit, Dalma Seboek Kinter, David Mayleben, Ingo Fietze, Yves Dauvilliers, Claudio L. Bassetti, Emmanuel Mignot, Damien Léger, Thomas Roth and Jan Hedner and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer.

In The Last Decade

Scott Pain

16 papers receiving 444 citations

Hit Papers

Safety and efficacy of daridorexant in patients with inso... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
    2022 136 citations Emmanuel Mignot, David Mayleben et al. The Lancet Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Pain Switzerland 7 333 319 234 84 41 18 461
Naoki Kubota Japan 8 216 0.6× 219 0.7× 137 0.6× 55 0.7× 39 1.0× 38 417
Machiko Kiyokawa Japan 11 124 0.4× 61 0.2× 269 1.1× 48 0.6× 37 0.9× 18 500
Hideki Sano Japan 8 66 0.2× 26 0.1× 210 0.9× 138 1.6× 45 1.1× 10 368
Dinah Faith T. Quiton United States 7 49 0.1× 110 0.3× 188 0.8× 39 0.5× 12 0.3× 8 341
Benjamin L. Adams United States 8 71 0.2× 45 0.1× 62 0.3× 125 1.5× 10 0.2× 13 276
Kenneth I. Porter United States 8 26 0.1× 46 0.1× 207 0.9× 67 0.8× 3 0.1× 14 348
Todd A. Ponzio United States 15 22 0.1× 13 0.0× 155 0.7× 92 1.1× 17 0.4× 25 423
Yusuke Masuda Japan 7 158 0.5× 138 0.4× 6 0.0× 72 0.9× 5 0.1× 11 354
Sandy Wilson United States 9 30 0.1× 17 0.1× 52 0.2× 167 2.0× 5 0.1× 19 389
Martine Germain France 11 62 0.2× 13 0.0× 100 0.4× 109 1.3× 5 0.1× 12 331

Countries citing papers authored by Scott Pain

Since Specialization
Citations

This map shows the geographic impact of Scott Pain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Pain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Pain more than expected).

Fields of papers citing papers by Scott Pain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Pain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Pain. The network helps show where Scott Pain may publish in the future.

Co-authorship network of co-authors of Scott Pain

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Pain. A scholar is included among the top collaborators of Scott Pain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Pain. Scott Pain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
3.
McElroy, Susan L., Preciosa M. Coloma, Benjamin Berger, et al.. (2023). Efficacy, safety, and tolerability of nivasorexant in adults with binge‐eating disorder: A randomized, Phase II proof of concept trial. International Journal of Eating Disorders. 56(11). 2120–2130. 9 indexed citations
4.
Fietze, Ingo, Claudio L. Bassetti, David Mayleben, et al.. (2022). Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial. Drugs & Aging. 39(10). 795–810. 34 indexed citations
5.
Mignot, Emmanuel, David Mayleben, Ingo Fietze, et al.. (2022). Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. The Lancet Neurology. 21(2). 125–139. 136 indexed citations breakdown →
6.
Fietze, Ingo, Claudio L. Bassetti, David Mayleben, et al.. (2022). Effects of daridorexant on sleep and daytime functioning in older adults with insomnia. American Journal of Geriatric Psychiatry. 30(4). S69–S70. 3 indexed citations
7.
Léger, Damien, Ingo Fietze, Scott Pain, et al.. (2021). 348 Absence of Withdrawal Symptoms and Rebound Insomnia Upon Discontinuation of Daridorexant in Patients with Insomnia. SLEEP. 44(Supplement_2). A139–A139. 4 indexed citations
8.
Fietze, Ingo, Claudio L. Bassetti, David Mayleben, et al.. (2021). 347 Daridorexant is Safe and Improves Both Sleep and Daytime Functioning in Elderly Patients with Insomnia. SLEEP. 44(Supplement_2). A138–A139. 3 indexed citations
9.
Zammit, Gary, David Mayleben, Ingo Fietze, et al.. (2021). 344 Daridorexant Improves Total Sleep Time (TST) in Insomnia Patients Without Altering the Proportion of Sleep Stages. SLEEP. 44(Supplement_2). A137–A138. 1 indexed citations
10.
Dauvilliers, Yves, Gary Zammit, Ingo Fietze, et al.. (2020). Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder. Annals of Neurology. 87(3). 347–356. 103 indexed citations
11.
12.
Zammit, Gary, et al.. (2020). Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 94(21). e2222–e2232. 78 indexed citations
13.
Dauvilliers, Yves, Gary Zammit, Ingo Fietze, et al.. (2019). 0375 A Novel Dual Orexin Receptor Antagonist (ACT-541468) to Treat Insomnia: A Randomized, Double-Blind, Placebo-Controlled, Active-Reference Phase 2 Study. SLEEP. 42(Supplement_1). A152–A153. 1 indexed citations
14.
Zammit, Gary, Yves Dauvilliers, Scott Pain, Dalma Seboek Kinter, & Dieter Kunz. (2019). 0407 ACT-541468, A Dual Orexin Receptor Antagonist, For The Treatment Of Insomnia Disorder: A Randomized, Double-Blind, Placebo-Controlled, 5-Period, 5-Treatment Crossover Dose-Response Phase 2 Study In The Elderly. SLEEP. 42(Supplement_1). A165–A165. 1 indexed citations
15.
Spreafico, Anna, J.P. Delord, Leticia De Mattos‐Arruda, et al.. (2015). A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. British Journal of Cancer. 112(4). 650–659. 27 indexed citations
16.
Seggewiss‐Bernhardt, Ruth, Ralf C. Bargou, Yeow Tee Goh, et al.. (2015). Phase 1/1B trial of the heat shock protein 90 inhibitor NVP‐AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer. 121(13). 2185–2192. 52 indexed citations
17.
Mattos‐Arruda, Leticia De, Lillian L. Siu, Javier Cortés, et al.. (2013). Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.. Journal of Clinical Oncology. 31(15_suppl). 2561–2561. 4 indexed citations
18.
Yeh, Kun‐Huei, Jen‐Shi Chen, Alberto F. Sobrero, et al.. (2012). P-0303 Safety and Tolerability data from A Phase II Study of Auy922 Compared with Chemotherapy in Patients with Advanced Gastric Cancer. Annals of Oncology. 23. iv118–iv118. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naoki Kubota Breakdown of academic impact, for papers by Machiko Kiyokawa Breakdown of academic impact, for papers by Hideki Sano Breakdown of academic impact, for papers by Dinah Faith T. Quiton Breakdown of academic impact, for papers by Benjamin L. Adams Breakdown of academic impact, for papers by Kenneth I. Porter Breakdown of academic impact, for papers by Todd A. Ponzio Breakdown of academic impact, for papers by Yusuke Masuda Breakdown of academic impact, for papers by Sandy Wilson Breakdown of academic impact, for papers by Martine Germain
Rankless by CCL
2026